Sk Biopharmaceuticals Co Ltd (326030)

Seoul
87,700
0(0.00%)
  • Volume:
    94,538
  • Bid/Ask:
    87,600/87,700
  • Day's Range:
    87,000 - 89,200

326030 Overview

Prev. Close
87,700
Day's Range
87,000-89,200
Revenue
319.8B
Open
87,800
52 wk Range
73,000-137,000
EPS
-1,268.63
Volume
94,538
Market Cap
6.87T
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
89,855
P/E Ratio
-
Beta
-
1-Year Change
-19.82%
Shares Outstanding
78,313,250
Next Earnings Date
May 27, 2022
What is your sentiment on Sk Biopharma?
or
Market is currently closed. Voting is open during market hours.

Sk Biopharmaceuticals Co Ltd News

Sk Biopharmaceuticals Co Ltd Company Profile

Sk Biopharmaceuticals Co Ltd Company Profile

Employees
0

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders. The company is developing Cenobamate for the treatment of epilepsy; Solriamfetol for the treatment of excessive daytime sleepiness in narcolepsy or obstructive sleep apneal; Carisbamate that is in Phase 1b/2 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials to treat rare neurological disease. It is also developing SKL13865 that is in Phase 1 clinical trials to treat attention deficit/hyperactivity disorder; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder; and SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy. The company was founded in 2011 and is headquartered in Seongnam, South Korea. SK Biopharmaceuticals Co., Ltd. operates as subsidiary of SK Inc.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyBuyBuySell
Technical IndicatorsStrong BuyBuyNeutralBuyStrong Sell
SummaryStrong BuyStrong BuyNeutralBuyStrong Sell